Fig. 8

TWF9 treatment does not affect astrocyte or microglia levels. a Representative images of GFAP-positive astrocytes shown with GFAP immunoreactivity in subiculum of old 3xTg-AD mice. Scale bar = 100 μm. b Analysis of GFAP immunoreactivity measured as percentage of subiculum area covered by astrocytes. Quantification of GFAP staining in the subiculum from two to four sections per mouse of all animals (****p < 0.0001 by Kruskal-Wallis test followed by Dunn’s multiple comparisons test); n = 11 for transgenic (Tg) treated (Tx), n = 12 for Tg saline, n = 11 for nontransgenic (NTg) Tx, n = 9 for NTg saline. Data are expressed as mean ± SD. Quantification of GFAP immunoreactivity for NTg Tx vs Tg Tx (****p < 0.0001), NTg Tx vs Tg saline (***p < 0.001), NTg saline vs Tg Tx (***p < 0.001), and NTg saline vs Tg Saline (**p < 0.01). c Representative images of resting and active microglia shown with IBA1 immunoreactivity in subiculum of old 3xTg-AD mice. d Analysis of IBA1 immunoreactivity measured as percentage of subiculum area covered by microglia. Quantification of IBA1 staining in the subiculum from two to four sections per mouse; n = 11 for Tg Tx, n = 12 for Tg saline, n = 4 for NTg Tx, n = 4 for NTg saline. Data are expressed as mean ± SD. Analyzed by one-way ANOVA followed by Tukey’s multiple comparisons test